On the 5th, Honz Pharmaceutical Co.Ltd(300086) replied to the inquiry letter of Shenzhen Stock Exchange, saying that there was no disclosure of inside information; The main business operation is normal, and there are no major adverse factors affecting the sustainable operation.
Honz Pharmaceutical Co.Ltd(300086) also said in the reply to the announcement that recently, because the traditional Chinese medicine plate in the stock market was concerned by the market and showed a strong trend as a whole, the company, as a pharmaceutical enterprise with the ability to produce traditional Chinese medicine and multiple production approvals of traditional Chinese medicine products, also attracted extensive attention from the market. Recently, the company’s share price has increased greatly, which is of great concern. In strict accordance with the relevant provisions of China Securities Regulatory Commission and Shenzhen Stock Exchange, the company has timely fulfilled the obligation of information disclosure to ensure the openness and transparency of the information of listed companies.
On the secondary market, Honz Pharmaceutical Co.Ltd(300086) share price has risen sharply in recent days. In the four trading days from December 27 to December 30, 2021, the range has increased by 76.15%, of which the share price has increased by 20% on December 27 and December 29. On December 30, the stock price of Honz Pharmaceutical Co.Ltd(300086) stood at 10.00 yuan, a record high.
On the same day, the Shenzhen Stock Exchange issued a concern letter asking Honz Pharmaceutical Co.Ltd(300086) to explain whether the controlling shareholder and the actual controller have major events in the planning stage and whether there is any leakage of insider information; Whether the development of main business faces major adverse factors and whether there is uncertainty in the ability of sustainable operation; Whether the relevant entities have insider trading, market manipulation, etc.
In this regard, in the latest reply announcement, Honz Pharmaceutical Co.Ltd(300086) said that through self-examination and written inquiry and verification to the company’s directors, supervisors, senior managers, controlling shareholders and actual controllers, the company, controlling shareholders and actual controllers have no major events in the planning stage and no disclosure of insider information, the company and controlling shareholders The actual controller has no material information that should be disclosed but not disclosed.
Meanwhile, in the past three months, the company has not violated the principle of fairness of information disclosure or misled investors, nor has it disclosed in advance, should it be disclosed but not disclosed, or misleadingly disclosed.
Honz Pharmaceutical Co.Ltd(300086) also said that the controlling shareholders, actual controllers, shareholders holding more than 5%, directors, supervisors, senior managers and their immediate family members of the company do not have insider trading and market manipulation.
In terms of financial data, in the first three quarters of 2021, Honz Pharmaceutical Co.Ltd(300086) the net profit attributable to the shareholders of the parent company was a loss of 41.6055 million yuan, a year-on-year decrease of 2049.65%; The net cash flow from operating activities was -34.8737 million yuan.
In this regard, Honz Pharmaceutical Co.Ltd(300086) said that the net profit loss was mainly due to the decrease of operating revenue and the increase of expense investment; The net cash flow from operating activities was negative, mainly due to the increase in the payment for goods received in 2021 and the decrease in the expenditure on purchasing epidemic products and production materials compared with the same period in 2020. The company’s main business operates normally, has not faced major adverse factors and impacts on its sustainable operation, and there is no uncertainty about its sustainable operation ability.
According to the data, Honz Pharmaceutical Co.Ltd(300086) was established in January 1994 and is registered in Haikou City, Hainan Province. The largest shareholder is Hainan Hongshi Investment Co., Ltd., which is a private listed company focusing on children’s medicine. It has a children’s drug cluster with “Kangzhi” as the main brand, and has launched products such as “ruizhiqing”, “kangzhisong”, “kangzhitai” and “jinlishuang”.
As of the closing on January 5, Honz Pharmaceutical Co.Ltd(300086) fell 12.06% and quoted 7.44 yuan.
(Zhongxin Jingwei)
